Evidence map›Paper›PMID 24944242›Full record

Trial reportAmerican journal of physiology. Regulatory, integrative and comparative physiology2014

Characterization of the effects of the vasopressin V2 receptor on sweating, fluid balance, and performance during exercise.

Tamara Hew-Butler, Jed Hummel, Brian C Rider, Joseph G Verbalis

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in American journal of physiology. Regulatory, integrative and comparative physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Physiological mechanisms determining eccrine sweat composition.European journal of applied physiology · 2020
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Interindividual variability in sweat electrolyte concentration in marathoners.Journal of the International Society of Sports Nutrition · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Tamara Hew-ButlerExercise Science Program, Oakland University, Rochester, Michigan; and hew@oakland.edu.
Jed HummelExercise Science Program, Oakland University, Rochester, Michigan; and.
Brian C RiderExercise Science Program, Oakland University, Rochester, Michigan; and.
Joseph G VerbalisEndocrinology and Metabolism, Georgetown University Medical Center, Washington, DC.
Oakland University · USGeorgetown University · US

Funding

NCATS NIH HHS UL1TR00010
6 · The paper itself

Abstract

A regulatory effect of arginine vasopressin (AVP) on sweat water conservation has been hypothesized but not definitively evaluated. AVP-mediated insertion of sweat and salivary gland aquaporin-5 (AQP5) water channels through activation of the vasopressin type 2 receptor (V2R) remains an attractive, yet unexplored, mechanism that could result in a more concentrated sweat with resultant decreased water loss. Ten runners participated in a double-blind randomized control treadmill trial under three separate pharmacological conditions: a placebo, V2R agonist (0.2 mg desmopressin), or V2R antagonist (30 mg tolvaptan). After a familiarization trial, runners ran for 60 min at 60% of peak speed followed by a performance trial to volitional exhaustion. Outcome variables were collected at three exercise time points: baseline, after the steady-state run, and after the performance run. Body weight losses were <2% across all three trials. Significant pharmacological condition effects were noted for urine osmolality [F = 84.98; P < 0.0001] and urine sodium concentration ([Na(+)]) [F = 38.9; P < 0.0001], which verified both pharmacological activation and inhibition of the V2R at the kidney collecting duct. Plasma osmolality and [Na(+)] demonstrated significant exercise (F = 26.0 and F = 11.1; P < 0.0001) and condition (F = 5.1 and F = 3.8; P < 0.05) effects (osmolality and [Na(+)], respectively). No significant exercise or condition effects were noted for either sweat or salivary [Na(+)]. Significant exercise effects were noted for plasma [AVP] (F = 22.3; P < 0.0001), peak core temperature (F = 103.3; P < 0.0001), percent body weight change (F = 6.3; P = 0.02), plasma volume change (F = 21.8; P < 0.0001), and thirst rating (F = 78.2; P < 0.0001). Performance time was not altered between conditions (P = 0.80). In summary, AVP acting at V2R does not appear to regulate water losses from body fluids other than renal excretion during exercise.

Indexed as

ExercisePhysical EnduranceSweatingWater-Electrolyte BalanceAdultAntidiuretic Hormone Receptor AntagonistsBenzazepinesBiomarkersDeamino Arginine VasopressinDouble-Blind MethodFemaleHormone AntagonistsHumansMaleMiddle AgedNeurophysinsAntidiuretic Hormone Receptor AntagonistsAVP protein, humanAVPR2 protein, humanBenzazepinesBiomarkersDeamino Arginine VasopressinHormone AntagonistsNeurophysinsProtein PrecursorsReceptors, VasopressinSodiumTolvaptanVasopressinsarginine vasopressinrunningsweat sodiumV2 antagonist

Identifiers

PMID24944242
PMCPMC4137153
OpenAlexW1998517633

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.